Recent Updates
Recently added Catalysts
RLAY Neutral Sentiment Score: 50/100

Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

Thursday, February 16, 2023 1 min read
Key Takeaway: CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report fourth quarter a

Market Sentiment Analysis

Full Press Release Details

CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report fourth quarter and full year 2022 financial results and corporate highlights after the close of market on Thursday, February 23, 2023. The company will not be conducting a teleconference in conjunction with its financial results press release.
About Relay Therapeutics

Frequently Asked Questions

What is Relay Therapeutics?

Relay Therapeutics is a biopharmaceutical company focused on innovative therapies.

How can I contact Relay Therapeutics?

You can contact Relay Therapeutics through Caroline Glen at 617-370-8837.

Who handles media inquiries for Relay?

Dan Budwick is the media contact for Relay Therapeutics.

What is the media contact's phone number?

Dan Budwick can be reached at 973-271-6085.

What is Caroline Glen's email address?

Caroline Glen's email is cglen@relaytx.com.

Tags: RLAY Viatris Investor Conferences Healthcare Relay Therapeutics 2022 results financial announcement corporate highlights
Last updated: Feb 16, 2023